IL2 and cancer: Reducing miR-15/16 expression might be beneficial in cancer immunotherapies where decreased IL-2 sensitivity in Tregs could limit IL-2-induced Treg amplification while maintaining IL-2 responsiveness in tumor-infiltrating lymphocytes.